Company profile
BOSTON SCIENTIFIC CORP
NYSE:BSXMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VARITHENA | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (40)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00479765 | phase1_2 | terminated | 2007-03-01 | 2009-10-01 | Boston Scientific Corporation | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma |
| NCT00528021 | phase2 | completed | 2007-08-01 | 2008-05-01 | Boston Scientific Corporation | A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation |
| NCT02460991 | phase3 | terminated | 2015-11-01 | 2017-06-05 | Boston Scientific Corporation | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma |
| NCT01037907 | phase2 | terminated | 2009-11-01 | 2011-12-01 | Boston Scientific Corporation | A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) |
| NCT00928421 | phase2 | completed | 2009-06-01 | 2009-12-01 | Boston Scientific Corporation | An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 205098 | 2013-11-25 | NDA | BOSTON SCIENTIFIC CORP | |||||
Loading… | ||||||||